We’re excited to announce that The Peptide Daily Brief has been invited to showcase Stack Tracker at the upcoming Healthspan Summit (📍Southern California). This is one of the premier longevity and health optimization events — and we’re raffling off 2 Expo tickets to our community. 👉 To enter: - Comment “Enter me” below. - You must be a member of The Peptide Daily Brief Skool group to qualify. - Please only enter if you are 100% sure you can attend (live in or will be visiting Southern California). - Winners will need to provide name, email, and phone number so the digital passes can be sent. - Raffle closes at midnight, September 30th. Winners will be announced immediately after. 📌 If you’re seeing this post shared in another Skool group, please use the link at the bottom to join TPDB and submit your entry on the main page. 🌐 Why This Matters for TPDB & Stack Tracker Community This event is a huge opportunity for us as a community: - We’ll be mingling, networking, and meeting investors to take Stack Tracker to the next level. - Current members locked in before our upcoming v3.0 launch will keep lifetime pricing — no matter how many advanced tools we bake in. - We’re planning live streams parts of the event to the TPDB Skool group so you can be part of the experience. - We’re lining up industry leaders for podcast recordings as the TPDB Rumble channel and podcast continue to grow. - Our goal is to create the most comprehensive ecosystem of thought leaders, tools, information, and influence in this space — and in doing so, bring the most value to our community and the communities that give us the privilege of contributing to their members. Your support is what makes this possible. This raffle is our way of giving back and making sure some of you can join us in person. 📱 Learn more about the Healthspan Summit here: healthspanevents.com Follow Healthspan Summit on social: - Instagram - LinkedIn - Facebook

The State of Texas has filed suit against Eli Lilly, accusing the pharma giant of bribing providers to prescribe its blockbuster GLP-1 drugs Mounjaro and Zepbound . According to court filings, Lilly funneled kickbacks to clinics and prescribers to ensure its products dominated the pipeline — while patients were quietly denied their right to smaller, safer doses from compounding pharmacies. The corruption goes beyond money changing hands. It’s a direct assault on patient choice. Doctors, incentivized by corporate payouts, steer prescriptions away from compounding pharmacies that specialize in individualized dosing. Even when patients request it, their prescriptions are blocked. That’s not medicine. That’s cartel behavior. And in a bizarre twist, Lilly’s legal defense has even cited Reddit threads about side effects as “evidence” in their case . A multi-billion-dollar corporation leaning on internet forums to shape the narrative shows just how flimsy their defense really is. 🕵️ The Playbook This lawsuit shines a light on a well-worn Big Pharma strategy: 1. Bribe prescribers → Secure dominance in clinics and telehealth pipelines. 2. Block competition → Deny patients access to compounding pharmacies offering safer, lower-dose options. 3. Control the dose → Engineer mega-dose protocols that maximize profit, not safety. 4. Weaponize the narrative → Smear smaller compounders and self-directed care as “unsafe” while scraping Reddit to justify their monopoly. 💊 Why the Dose Matters Paracelsus said it centuries ago: “The dose makes the poison.” Big Pharma has learned to engineer the perfect profit dose — not the safest dose. Why? - Production costs: It costs pennies to make these molecules. - Insurance coverage: Only certain dosing levels trigger maximum reimbursement. - Profit calculus: Push the highest dose that balances manufacturing cost and insurance payouts, even if it drives more side effects. The side effects aren’t a flaw of the system — they’re built into the model. Because every new complication means more prescriptions, more insurance billing, and more revenue.

It’s one of the biggest red flags in medicine today: Safe compounds with decades of promising research get blacklisted, while risky, side-effect-laden patented drugs are pushed onto the public with billion-dollar marketing budgets. That’s not science. That’s regulatory capture. 🏛️ How Regulatory Capture Works The FDA is supposed to be the referee. But in practice, it’s deeply entangled with the very pharmaceutical companies it regulates. Many FDA advisors and decision-makers rotate in and out of industry jobs. Pharma companies fund large portions of the FDA’s operations through user fees. The result? The system serves shareholders before patients. - If a compound can’t be patented, it’s marked as unsafe, untested, or “not for human use.” - If a drug can be patented, even with questionable safety data, it’s fast-tracked and rubber-stamped. This isn’t just theory. We’re living it. 💊 The Peptide Example - BPC-157 & Thymosin Alpha-1 → pulled from compounding pharmacies despite low toxicity profiles and a mountain of pre-clinical evidence. - Semaglutide (Ozempic/Wegovy) → greenlit, patented, and prescribed en masse, even as reports of side effects pile up. - Compounding pharmacies → once lifelines for affordable, tailored care, now targeted and restricted for offering unpatentable options. When regulators attack peptides under the guise of safety while blessing high-risk patented drugs, the bias is obvious. 🔄 The Playbook This is how the cycle works: 1. Suppress affordable, non-patentable compounds like peptides by reclassifying them as “unapproved drugs.” 2. Create a vacuum in patient access. 3. Introduce pharma-controlled alternatives with patents, clinical trial data, and aggressive marketing. 4. Monetize the monopoly. It’s not about protecting you. It’s about protecting a business model. 🧨 Why This Matters If regulators succeed in erasing peptides, it sets the stage for everything else: hormones, biologics, regenerative compounds, and even lifestyle enhancers.

Pharma knows that if non-patentable compounds gain traction, it threatens their model. You can’t charge $1,000/month for something anyone can compound for pennies. So the strategy is simple: - Reclassification → Call peptides “unapproved drugs” or “biologics” instead of research tools. - Scheduling → Group them with controlled substances, even though they have no abuse profile. - Enforcement → Target compounding pharmacies that offer affordable access. - Narrative control → Spread fear about “unregulated peptides” while fast-tracking riskier, profitable drugs through the approval system. By moving the goalposts, they make it so the only peptides available are the ones they control, at the price they set. 💊 The Double Standard in Action - Semaglutide (Ozempic/Wegovy): Greenlit, patented, and marketed aggressively. Yet compounding versions were attacked when shortages hit. - BPC-157, Thymosin Alpha-1, Epitalon: Anecdotally effective with low risk profiles, but swept from the market under the guise of “safety.” - TRT & Hormones: Once taboo, now carefully reintroduced — but only within strict, expensive pharma channels. The pattern is clear: suppress anything unpatentable, promote anything profitable. 🧨 Why Peptides Are the Canary in the Coal Mine This isn’t just about peptides. If they win here, the same logic applies to: - Hormones - Biologics - Regenerative compounds - Even lifestyle-enhancing molecules are still in development If access to peptides disappears, so does the precedent for personal choice in future therapies. That’s why the peptide fight is the fight. It decides the boundaries of personal health, longevity, and freedom for decades to come. 🌐 Why We Are The Peptide Daily Brief We named this platform The Peptide Daily Brief because peptides are the battleground that reveals the system’s true face. If we lose peptides, we lose far more than access to a handful of research compounds. We lose the right to explore, experiment, and optimize outside the walls of corporate-controlled medicine.

For anyone who’s been on the fence about trying Stack Tracker, the door just opened wider. We’ve made some major updates to how subscriptions work — and it’s now easier than ever to test drive the app without any commitment: ✅ 14-Day Free Trial → Get full access to every feature for two weeks, completely free. ✅ Flexible Plans → Choose monthly or annual billing, and switch anytime. ✅ Smooth Checkout → The new setup is faster, easier, and more cohesive. ✅ Skool Community Access → And of course, you get into the Skool group, so you’re not testing the app in isolation — you’re learning from others in real time. The goal here is simple: no more hesitation, no more barriers. You can jump in today, explore the features, log your first protocols, and see if Stack Tracker fits your research flow — before spending a dime. Head over to Stack Tracker and get started today!